Cmp Dev Llc patent expiration

1. Atorvaliq patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11925704 CMP DEV LLC Aqueous suspension suitable for oral administration
Jun, 2037

(12 years from now)

US11654106 CMP DEV LLC Aqueous suspension suitable for oral administration
Jun, 2037

(12 years from now)

US11369567 CMP DEV LLC Aqueous suspension suitable for oral administration
Jun, 2037

(12 years from now)




Drugs and Companies using ATORVASTATIN CALCIUM ingredient

Market Authorisation Date: 01 February, 2023

Treatment: Method for lowering cholesterol level in a human; As an adjunct to other low-density lipoprotein cholesterol (ldl-c) lowering therapies, or alone if such treatments are unavailable, to reduce ldl-c in...

Dosage: SUSPENSION

More Information on Dosage

ATORVALIQ family patents

Family Patents

2. Carospir patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11395828 CMP DEV LLC Spironolactone aqueous compositions
Oct, 2036

(12 years from now)

US9757394 CMP DEV LLC Spironolactone aqueous formulations
Oct, 2036

(12 years from now)

US10493083 CMP DEV LLC Spironolactone aqueous compositions
Oct, 2036

(12 years from now)

US10624906 CMP DEV LLC Spironolactone aqueous compositions
Oct, 2036

(12 years from now)

US10660907 CMP DEV LLC Spironolactone aqueous compositions
Oct, 2036

(12 years from now)

US11389461 CMP DEV LLC Spironolactone aqueous compositions
Oct, 2036

(12 years from now)

US11491166 CMP DEV LLC Spironolactone aqueous compositions
Oct, 2036

(12 years from now)

US10888570 CMP DEV LLC Spironolactone aqueous compositions
Oct, 2036

(12 years from now)




Drugs and Companies using SPIRONOLACTONE ingredient

Market Authorisation Date: 04 August, 2017

Treatment: Carospir is indicated for the management of edema in adult cirrhotic patients when edema is not responsive to fluid and sodium restriction; Carospir is indicated for treatment of nyha class iii-iv hea...

Dosage: SUSPENSION

How can I launch a generic of CAROSPIR before it's drug patent expiration?
More Information on Dosage

CAROSPIR family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Liqrev patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11464778 CMP DEV LLC Liquid oral formulations for sildenafil
Dec, 2038

(14 years from now)

US11337979 CMP DEV LLC Liquid oral formulations for sildenafil
Dec, 2038

(14 years from now)

US11759468 CMP DEV LLC Liquid oral formulations for sildenafil
Dec, 2038

(14 years from now)




Drugs and Companies using SILDENAFIL CITRATE ingredient

Market Authorisation Date: 28 April, 2023

Treatment: Liqrev is indicated for the treatment of pulmonary arterial hypertension (who group 1) in adults to improve exercise ability and delay clinical worsening

Dosage: SUSPENSION

More Information on Dosage

LIQREV family patents

Family Patents

4. Norliqva patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11458095 CMP DEV LLC Pharmaceutical solution of amlodipine
Feb, 2041

(16 years from now)

US11723866 CMP DEV LLC Pharmaceutical solution of amlodipine
Feb, 2041

(16 years from now)

US11253474 CMP DEV LLC Pharmaceutical solution of amlodipine
Feb, 2041

(16 years from now)




Drugs and Companies using AMLODIPINE BESYLATE ingredient

Market Authorisation Date: 24 February, 2022

Treatment: Norliqva is indicated for the treatment of confirmed or suspected vasospastic angina; Norliqva is indicated for the symptomatic treatment of chronic stable angina

Dosage: SOLUTION

More Information on Dosage

NORLIQVA family patents

Family Patents

5. Potassium Phosphates patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10632150 CMP DEV LLC Potassium phosphates composition for injection
Apr, 2039

(14 years from now)




Drugs and Companies using POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC ingredient

Market Authorisation Date: 19 September, 2019

Treatment: Potassium phosphates injection is indicated as a source of phosphorus in intravenous fluids to correct hypophosphatemia in adults and pediatric patients 12 years of age and older

Dosage: SOLUTION

More Information on Dosage

POTASSIUM PHOSPHATES family patents

Family Patents

6. Tadliq patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11666576 CMP DEV LLC Liquid oral formulations for tadalafil
Dec, 2038

(14 years from now)

US11382917 CMP DEV LLC Liquid oral formulations for tadalafil
Dec, 2038

(14 years from now)




Drugs and Companies using TADALAFIL ingredient

Market Authorisation Date: 17 June, 2022

Treatment: Tadliq is indicated for the treatment of pulmonary arterial hypertension (pah) (who group 1) to improve exercise ability

Dosage: SUSPENSION

More Information on Dosage

TADLIQ family patents

Family Patents